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Background: Leukocytes play an important role in cancer development. However, the impact of chemotherapy-
associated neutropenia/lymphopenia on the prognosis of adjuvant chemotherapy is unknown. Here, we aimed to
explore the impact of chemotherapy-associated neutrophil/lymphocyte counts on prognosis of adjuvant
chemotherapy in colorectal cancer (CRC) and the risk factors for developing neutropenia/lymphopenia which
showed impact on the prognosis of CRC receiving adjuvant chemotherapy.
Methods: From February 2003 to January 2011, 243 stage II and III CRC patients receiving adjuvant chemotherapy
were enrolled in this retrospective study. The associations between neutrophil/ lymphocyte counts and disease free
survival (DFS)/overall survival (OS) of CRC, and the risk factors for neutropenia/lymphopenia were investigated.
Results: No association of chemotherapy-associated neutrophil counts and CRC recurrence (AUC = 0.474, P = 0.534),
death (AUC = 0.449, P = 0.249) was found by ROC analysis. However, the chemotherapy-associated lymphocyte
counts could significantly affect CRC recurrence (AUC = 0.634, P = 0.001), or death(AUC = 0.607, P = 0.015), with a
optimized cut-off of 0.66 × 109/L for recurrence, and 0.91 × 109/L for death, respectively. Kaplan–Meier method
showed chemotherapy-associated lymphopenia <0.66 × 109/L was associated with shorter DFS (P < 0.0001), and
chemotherapy-associated lymphopenia <0.91 × 109/L was associated with shorter OS (P = 0.003). Cox regression
model showed chemotherapy-associated lymphopenia <0.66 × 109/L was the independent prognostic factor for
DFS (HR, 3.521; 95%CI = 1.703-7.282), and chemotherapy-associated lymphopenia <0.91 × 109/L was the
independent prognostic factor for OS (HR, 2.083; 95% CI = 1.103-3.936). Multivariate logistic regression showed the
risk of developing chemotherapy-associated lymphopenia <0.66 × 109/L was found in those with pretreatment
CEA ≥10 ng ml-1 (OR, 3.338; 95% CI = 1.523-7.315), and the risk of developing chemotherapy-associated
lymphopenia <0.91 × 109/L was found in those with age >60 years (OR, 2.872; 95% CI = 1.344-6.136).
Conclusions: Chemotherapy-associated lymphopenia <0.66 × 109/L /0.91 × 109/L has a significant impact on the
prognosis of CRC receiving adjuvant chemotherapy. Pretreatment CEA ≥10 ng ml-1 is the independent risk factor
for developing lymphopenia <0.66 × 109/L, and age >60 years is the independent risk factor for developing
lymphopenia <0.91 × 109/L during adjuvant chemotherapy of CRC.
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Colorectal cancer (CRC) is increasing in the world and
China in recent years [1-3]. 5-Fu-based chemotherapy
has been used to reduce the risk of relapse after surgery.
5-Fu plus leucovorin with the addition of oxaliplatin
chemotherapy(FOLFOX), which improved survival signifi-
cantly compared with 5-FU alone [4], has been widely ac-
cepted as the standard adjuvant chemotherapy for stage
III and stage II colorectal cancer. However, stage III pa-
tients have a 50–60% likelihood of tumor recurrence, and
20–30% of stage II patients will show recurrent disease
[5]. Therefore, it is very important to select subgroups of
patients who are most likely to be resistant to a given
chemotherapy regimen.
In the past decades, several biomarkers such as micro-
satellite instability [6], Chromosome 18q allelic loss [7],
TP53 mutation/overexpression [8,9], thymidylate syn-
thase overexpression [9], Ki-67 overexpression [9], have
been found to be associated with prognosis of colorectal
cancer. However, some other reports failed to demon-
strate the prognostic/predictive effect of the biomarkers
mentioned above [10-12]. Thereby it is critical to iden-
tify the reliable biomarkers for prognosis of CRC pa-
tients receiving adjuvant chemotherapy. On the other
hand, leukocytes play an important role in cancer devel-
opment [13,14]. Thus, it seems that leukocytes variation
may have some impact on the survival of colorectal can-
cer. However, whether neutropenia and lymphopenia,
which are the common chemotherapy-induced toxicities,
may influence the prognosis of adjuvant chemotherapy
in CRC is unknown. Herein we explored the impact of
chemotherapy-associated neutrophil/ lymphocyte counts
on the prognosis of CRC patients receiving adjuvant
chemotherapy. We also examined the risk factors affect-
ing neutrophil or lymphocyte variation which showed
impact on the prognosis of CRC patients receiving adju-
vant chemotherapy to guide the individualized medicine
for patients with CRC requiring chemotherapy.
Methods
Patient selection
From February 2003 to January 2011, stage II and III
pathology-proven CRC patients who received FOLFOX
regimen as adjuvant chemotherapy in the Second Affili-
ated Hospital of Guangzhou Medical University were en-
rolled in our retrospective study. Other eligibility criteria
were as follows: At least 3 cycles of adjuvant chemother-
apy, no tumor recurrence during chemotherapy, WHO
performance status (PS) 0–1, adequate pretreatment renal
(pretreatment creatinine clearance ≥60 mL/min), and hep-
atic functions (pretreatment bilirubin ≤1.5 upper limit of
normal, pretreatment alanine aminotransferase and/or as-
partate aminotransferase ≤2.5 upper limit of normal), ad-
equate baseline bone marrow (absolute baseline neutrophilcounts ≥ 2.0 × 109 cells/L, absolute baseline lymphocyte
counts ≥1.0 × 109 cells/L, baseline platelet counts ≥100 ×
109 cells/L). The exclusion criteria included the following:
biologic or immunotherapy, concomitant or neoadjuvant
radiotherapy, previous systemic chemotherapy or neo-
adjuvant chemotherapy, primary prophylactic administra-
tion of granulocyte colony-stimulating factor (G-CSF)
following chemotherapy, previous malignancies other than
colorectal cancer, documented human immunosuppres-
sion. The evaluation of WHO PS and blood cell counts
were performed before each next chemotherapy cycle and
the lowest blood cell count was recorded in our study. The
study was approved by the institutional review boards of
Guangzhou Medical University.
FOLFOX Treatment
The FOLFOX regimen consisted of a 2-h intravenous in-
fusion of oxaliplatin (85 mg/m2) and folinic acid (400 mg/
m2), followed by an intravenous bolus injection of 5-FU
(400 mg/m2) plus a 46-h intravenous infusion of 5-FU
(2400 mg/m2), repeated every 2 weeks. Chemotherapy
was delayed due to severe toxicity and the doses of
oxaliplatin and 5-FU were reduced by 15% in subsequent
cycles. Chemotherapy was discontinued due to unaccept-
able toxicity.
Data collection and assessment of adjuvant
chemotherapy prognosis
From the medical records we collected the data of
pretreatment albumin, pretreatment carcinoembryonic
antigen (CEA), differentiation, sex, age, location, stage,
blood cell counts. Albumin was divided into the follow-
ing two groups: ≥ or < 35 g/L. CEA was divided into the
following two groups: ≥ or < 10 ng ml-1. Duration of
neutropenia <1.5 × 109/L / lymphopenia <1.0 × 109 L was
divided into the following two groups: > 28 days or ≤28 -
days, respectively. Staging was performed according to
the American Joint Committee on Cancer (AJCC, sev-
enth edition).
Statistical analysis
The prognostic value of chemotherapy-associated neu-
trophil/lymphocyte counts on tumor recurrence, death
was analyzed by Receiver Operating Characteristic (ROC)
analysis to select the best cut-off of neutrophil/lymphocyte
counts. Kaplan–Meier method was used to estimate dis-
ease free survival (DFS) / overall survival (OS). Multivariate
analysis and Cox proportional hazard models were used to
determine the independent impact of chemotherapy-
associated neutrophil/lymphocyte counts on DFS/OS. The
risk factors for neutrophil or lymphocyte counts abnormal-
ity which showed impact on DFS/OS of stage II-III CRC
receiving adjuvant chemotherapy were analyzed by the un-
conditional logistic regression model. All statistical analyses
Table 1 Patient characteristics






≥35 g/L 173 71.2
<35 g/L 70 28.8
Pretreatment CEAa
≤10 ng/ml 186 76.5









≤49 years 56 23.0
50-60 yeas 72 29.6
>60 years 115 47.3
am
Rectum 111 45.7
Left colon cancer 77 31.7





Mean(± SD) 4.27 ± 1.49
Baseline lymphocyte counts(×109/L)
Mean(± SD) 1.88 ± 0.59
Chemotherapy-associated neutrophil counts
Neutrophil counts≥ 1.5 × 109/L 153 63.0
Neutropenia < 1.5 × 109/L 90 37.0
Chemotherapy-associated lymphocyte counts
Lymphocyte counts≥ 1.0 × 109/L 139 57.2
Lymphopenia < 1.0 × 109/L 104 42.8
a Carcinoembryonic antigen.
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17.0 software and 2-sided. P value <0.05 was considered to
be statistically significant.
Results
Characteristics of the study population
There were 243 CRC patients who fulfilled the eligibility
and exclusion criteria in the present study. The charac-
teristics of the studied population were shown in Table 1.
Of the 243 cases, 21 cases had to stop adjuvant chemo-
therapy for severe toxicity. The median age of 243 cases
was 59 years with a range of 22–82 years. The median
follow-up time was 31 months (range 7–103 months).
Of the 243 cases, 109(44.9%) were female and 134
(55.1%) were male. 111(45.7%) cases were rectal cancer,
77(31.7%) cases were left colon cancer, and 55 (22.6%)
were right colon cancer. According to the American
Joint Committee on Cancer (AJCC, seventh edition),
there were 140(57.6%) stage II cases and 103(42.4%)
stage III cases. The population in our study had a mean
baseline neutrophil counts of 4.27 ± 1.49 × 109/L, a mean
baseline lymphocyte counts of 1.88 ± 0.59 × 109/L. 90
(37.0%) cases experienced neutropenia <1.5 × 109/L and
104(42.8%) cases experienced lymphopenia <1.0 × 109/L
during chemotherapy. According to National Cancer
Institute Common Terminology Criteria for Adverse
Events version 3.0 (NCI-CTC), grade 3/4 neutropenia
was observed in 49(20.2%) cases and grade 3/4
lymphopenia was observed in 15(6.2%) cases. 4(1.6%)
cases suffered from neutropenic infection requiring
hospitalization and treatment with intravenous antibi-
otics at 5 cycles of chemotherapy.
The prognostic value of chemotherapy-associated
neutrophil/ lymphocyte counts on CRC recurrence/death
The cut-offs according to NCI-CTC may not be reliable
to evaluate the impact of chemotherapy-associated neu-
trophil/lymphocyte counts on the prognosis of CRC re-
ceiving adjuvant chemotherapy. We investigated the
prognostic value of chemotherapy-associated neutrophil/
lymphocyte counts on CRC recurrence, death by ROC
analysis to select the best cut-off. No association of
chemotherapy-associated neutrophil counts and tumor
recurrence, death was found. The area under curve
(AUC) of chemotherapy-associated neutrophil counts for
CRC recurrence, death was 0.474(P = 0.534), 0.449(P =
0.249), respectively (Figure 1). However, the significance
was found between chemotherapy-associated lymphocyte
counts and CRC recurrence, death. The AUC of
chemotherapy-associated lymphocyte counts, was 0.634
for CRC recurrence (P = 0.001), 0.607 for death (P = 0.015),
respectively (Figure 2). We then evaluated the best cut-off
of chemotherapy-associated lymphocyte level affecting
CRC recurrence, death with the highest value of sensitivityplus specificity by ROC analysis. The best prognostic cut-
off was 0.66 × 109/L for CRC recurrence, 0.91 × 109/L for
death, respectively. 42(17.3%) cases had chemotherapy-
associated lymphopenia < 0.66 × 109/L and 90(37.0%) cases
had chemotherapy-associated lymphopenia < 0.91 × 109/L
in this study.
Figure 1 ROC curve of chemotherapy-associated neutrophil counts affecting CRC recurrence, death. (A) The area under curve (AUC) of
chemotherapy-associated neutrophil counts for CRC recurrence was 0.474 and P value was 0.534. (B) The AUC of chemotherapy-associated
neutrophil counts for CRC death was was0.449 and P value was 0.249.
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lymphopenia <0.66 × 109/L, 0.91 × 109/L for colorectal
cancer
Therefore, we selected 0.66 × 109/L, 0.91 × 109/L which
were found by ROC analysis as the cut-offs to investigate
the impact of chemotherapy-associated lymphopenia on
DFS, OS of CRC receiving adjuvant chemotherapy.
Kaplan–Meier method showed chemotherapy-associated
lymphopenia <0.66 × 109/L was associated with shorter
DFS (P < 0.0001), whereas chemotherapy-associated
lymphopenia <0.91 × 109/L was associated with shorter
OS (P = 0.003) (Figure 3). To control the possible
confounding of the main effects of chemotherapy-
associated lymphopenia <0.66 × 109/L/0.91 × 109/L on
DFS/OS, respectively, the clinicopathological factorsFigure 2 ROC curve of chemotherapy-associated lymphocyte counts
chemotherapy-associated neutrophil counts for CRC recurrence was 0.634
neutrophil counts for CRC death was was 0.607 and P value was 0.015.(pretreatment albumin, pretreatment CEA, differenti-
ation, sex, age, location and stage) and duration of
lymphopenia <1.0 × 109 L were further adjusted for in
the multivariate cox regression model. As shown in
Table 2, cox regression model showed chemotherapy-
associated lymphopenia <0.66 × 109/L (HR, 3.521; 95%
CI = 1.703-7.282), pretreatment CEA ≥10 ng ml-1 (HR,
1.827; 95% CI = 1.040-3.211), stage III (HR, 2.723; 95%
CI = 1.549-4.786) were independent prognostic factors
for DFS, and 99 (40.7%) cases had all of those negative
prognostic factors. Moreover, as shown in Table 3, cox
regression model showed chemotherapy-associated lym-
phopenia <0.91 × 109/L (HR, 2.083 ; 95% CI = 1.103-3.936),
pretreatment CEA ≥10 ng ml-1 (HR, 1.900; 95% CI =
1.056-3.416), stage III (HR, 3.641; 95% CI = 1.980-6.697)affecting CRC recurrence, death. (A) The area under curve (AUC) of
and P value was 0.001. (B) The AUC of chemotherapy-associated
Figure 3 DFS, OS curve by Kaplan–Meier method. (A) Chemotherapy-associated lymphopenia <0.66 × 109/L was associated with shorter DFS
and P value was <0.0001. (B) Chemotherapy-associated lymphopenia <0.91 × 109/L was associated with shorter OS and P value was 0.003.
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(31.7%) cases had all of those negative prognostic factors.
The risk factors for chemotherapy-associated
lymphopenia <0.66×109/L /0.91 × 109/L in colorectal
cancer
Then the clinicopathological factors (pretreatment albu-
min, pretreatment CEA, differentiation, sex, age, loca-
tion, stage) were included in the multivariate logistic
regression model to explore the independent risk factors
for chemotherapy-associated lymphopenia <0.66 × 109/L/
0.91 × 109/L in colorectal cancer. As shown in Table 4
and Table 5, pretreatment CEA ≥10 ng ml-1 was the
independent risk factor for chemotherapy-associated
lymphopenia <0.66 × 109/L(OR, 3.338; 95% CI = 1.523-
7.315), and age >60 years was the independent risk fac-
tor for chemotherapy-associated lymphopenia <0.91 ×
109/L(OR, 2.872; 95% CI = 1.344-6.136).
Discussion
In the present study, we investigated the impact of
chemotherapy-associated neutrophil/lymphocyte counts
on prognosis of CRC receiving adjuvant chemotherapy.
We found chemotherapy-associated lymphopenia, but
not neutropenia to be associated with CRC recurrence,
death after adjuvant chemotherapy. The best lymphopenic
cut-off affecting CRC recurrence was 0.66 × 109/L, and that
affecting CRC death was 0.91 × 109/L. Chemotherapy-
associated lymphopenia <0.66 × 109/L/0.91 × 109/L was the
independent prognostic factor for worse DFS/OS, respect-
ively, in stage II and III CRC receiving adjuvant chemother-
apy. Pretreatment CEA ≥10 ng ml-1 was the independent
risk factor for chemotherapy-associated lymphopenia
<0.66 × 109/L, and age >60 years was the independent risk
factor for chemotherapy-associated lymphopenia <0.91 ×
109/L in CRC receiving adjuvant chemotherapy.It is reported that circulating lymphocytes play a central
role in anti-tumor effect. Lymphodepletion due to the al-
tered bone marrow microenvironment was observed in the
ApcMin/+ mouse model of intestinal tumorigenesis [15],
which indicates the lymphodepletion may contribute to the
drop of anti-tumor immune and tumorigenesis. Due to
interplay between soluble factors such as cytokines,
chemokines, surface receptors and adhesion molecules,
progression and invasion occur in a dynamic microenviron-
ment involving the complex communications between
tumor cells and many types of immune cells including the
various types of lymphocytes [16]. Thus,lymphopenia is
supposed to account for the adverse anti-tumor micro-
environment. Moreover, lymphopenia is associated with in-
creased circulating levels of IL-7 [17,18]. IL-7 plays an
oncogenic role promoting proliferation, lymphangiogenesis
and metastasis in neoplasm [19-23]. That may partly ex-
plain the clinical outcome of chemotherapy-associated
lymphopenia in colorectal cancer in our study. Recently,
pretreatment peripheral blood lymphocytes have been
found to show a significant impact on the complete re-
sponse rate in response to preoperative radiotherapy in lo-
cally advanced rectal cancer (RC) patients and lymphocyte-
mediated immune reactions are supposed to have positive
roles in radiosensitivity for RC [24]. Likewise, pretreatment
lymphopenia is an independent risk factor for shorter sur-
vival of palliative chemotherapy in colorectal cancer [25].
Moreover, pretreatment lymphopenia has been found to be
the independent risk factor for Peripheral T-cell lymphoma,
not otherwise specified (PTCL-NOS) [26], metastatic breast
carcinoma [27], advanced soft tissue sarcoma [27] and non-
Hodgkin's lymphoma [27]. Lymphopenia is a common ad-
verse event during chemotherapy with the incidence >25%
[28,29]. However, the clinical significance of chemotherapy-
associated lymphocyte drop in the adjuvant chemotherapy
of CRC is unclear. That indicated lymphopenia, which is
Table 2 Prognostic value of chemotherapy-associated lymphopenia <0.66 × 109/L for DFS of colorectal cancer
Variables Hazard ratio 95% confidence intervals P-value
Pretreatment albumin
≥35 g/L 1.00(ref.)
<35 g/L 1.000 0. 592–1. 692 0.999
Pretreatment CEAa
<10 ng ml-1 1.00(ref.)
≥10 ng ml-1 1. 827 1.040-3.211 0.036
Differentiation
Well 1.00(ref.)
Moderately 0. 676 0. 292–1.567 0.361
Low 0.882 0.294-2.644 0.823
Sex
Male 1.00(ref.)
Female 1.018 0.616-1.682 0.946
Age
≤49 years 1.00(ref.)
50-60 yeas 1.612 0.750-3.465 0.222
>60 years 1.386 0.673-2.854 0.376
Location
Rectum 1.00(ref.)
Left colon cancer 0.873 0.483-1.576 0.651
Right colon cancer 0.850 0.438-1.649 0.630
Stage
II 1.00(ref.)
III 2.723 1.549-4.786 0.001
Duration of lymphopenia <1.0 × 109 L
≤28 days 1.00(ref.)
> 28 days 0.556 0.243-1.273 0.165
Chemotherapy-associated lymphocyte counts
Lymphocyte counts≥ 0.66 × 109/L 1.00(ref.)
Lymphopenia <0.66 × 109/L 3.521 1.703-7.282 0.001
a Carcinoembryonic antigen.
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possible mechanism for the failure of adjuvant chemo-
therapy in CRC. Our study also showed chemotherapy-
associated neutropenia had no impact on DFS, OS of
CRC, suggesting lymphopenia rather than neutropenia
may play an important role in the variation of anti-
tumor immune reaction during adjuvant chemotherapy in
CRC. Chemotherapy-associated lymphopenia is reported
rarely in clinical trials. To the best of our knowledge, our
study demonstrated the impact of chemotherapy-associated
lymphopenia on the clinical outcome of adjuvant chemo-
therapy in CRC for the first time.
The cut-off of lymphopenia is different in previous stud-
ies. Some reports defined lymphopenia as a lymphocytecount of less than 1.5 × 109/L [30-32], while some other
reports chose the threshold level of 1.0 × 109/L [25,27].
However, when we chose the threshold level of 1.0 × 109/L
in the present study, lymphopenia <1.0 × 109/L was not
the independent risk factor for worse DFS,OS in stage II
and III CRC receiving adjuvant chemotherapy(data not
shown). Therefore, the cut-offs mentioned above may not
be suitable for the evaluation of lymphocyte counts on
prognosis of CRC receiving adjuvant chemotherapy. ROC
analysis showed the best cut-off of lymphopenia was 0.66 ×
109/L for CRC recurrence, <0.91 × 109/L for CRC death in
this study and Cox regression model as well as Kaplan–
Meier method confirmed the prognostic value of
lymphopenia <0.66 × 109/L for DFS,lymphopenia <0.91 ×
Table 3 Prognostic value of chemotherapy-associated lymphopenia <0.91 × 109/L for OS of colorectal cancer
Variables Hazard ratio 95% confidence intervals P-value
Pretreatment albumin
≥35 g/L 1.00(ref.)
<35 g/L 1.140 0.648-2.007 0.649
Pretreatment CEAa
<10 ng ml-1 1.00(ref.)
≥10 ng ml-1 1. 900 1.056-3.416 0.032
Differentiation
Well 1.00(ref.)
Moderately 0. 865 0. 323–2.314 0.772
Low 1.097 0.311-3.871 0.885
Sex
Male 1.00(ref.)
Female 0.856 0.493-1.489 0.583
Age
≤49 years 1.00(ref.)
50-60 yeas 1.514 0.625-3.666 0.359
>60 years 1.587 0.698-3.607 0.271
Location
Rectum 1.00(ref.)
Left colon cancer 1.067 0.564-2.019 0.843
Right colon cancer 0.647 0.296-1.414 0.275
Stage
II 1.00(ref.)
III 3.641 1.980-6.697 <0.0001
Duration of lymphopenia <1.0 × 109 L
≤28 days 1.00(ref.)
> 28 days 0.770 0.341-1.740 0.530
Chemotherapy-associated lymphocyte counts
Lymphocyte counts≥ 0.66 × 109/L 1.00(ref.)
Lymphopenia <0.66 × 109/L 2.083 1.103-3.936 0.024
a Carcinoembryonic antigen.
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associated lymphopenia <0.66 × 109/L/0.91 × 109/L is a
simple biomarker affecting worse DFS/OS,respectively, for
stage II and III CRC receiving adjuvant chemotherapy.
Lymphopenia <0.66 × 109/L/0.91 × 109/L can be the cut-
offs to guide the individualized medicine in adjuvant
chemotherapy of colorectal cancer.
Moreover, though chemotherapy associated lymphopenia
<0.66 × 109/L/0.91 × 109/L showed a longer duration of
duration of lymphopenia <1.0 × 109 L compared with
lymphopenia ≥0.66 × 109/L/0.91 × 109/L (80.76 ± 49.64 days
vs 7.43 ± 12.38 days, 51.84 ± 43.79 days vs 1.43 ± 5.01 days,
respectively, data not shown), cox regression modelshowed lymphopenia <0.66 × 109/L/0.91 × 109/L, but not
duration of lymphopenia <1.0 × 109 L, was the independent
prognostic factor. That suggest chemotherapy-associated
lymphopenia level, rather than duration of lymphopenia
<1.0 × 109/L, may play an important role in the prognosis
of CRC receiving adjuvant chemotherapy.
The previous studies reported lymphopenia could be
affected by various factors including vitamin D defi-
ciency [32], weight loss [33], variation of circulating
metal ions levels [34], malnutrition [35]. However, our
study showed pretreatment CEA ≥10 ng ml-1 was the
only independent risk factor for chemotherapy-associated
lymphopenia <0.66 × 109/L, and age >60 years was the
Table 4 The risk factors for chemotherapy-associated
lymphopenia <0.66 × 109/L in colorectal cancer by
multivariate logistic regression model
Variables Odds ratio 95% confidence intervals P-value
Pretreatment albumin
≥35 g/L 1.00(ref.)
<35 g/L 0.685 0.302-1.550 0.363
Pretreatment CEAa
<10 ng ml-1 1.00(ref.)
≥10 ng ml-1 3.338 1.523-7.315 0.003
Differentiation
Well 1.00(ref.)
Moderately 1.200 0.308-4.678 0.793
Low 3.049 0.553-16.828 0.201
Sex
Male 1.00(ref.)
Female 1.219 0.600-2.474 0.584
Age
≤49 years 1.00(ref.)
50-60 yeas 0.840 0.271-2.608 0.763
>60 years 2.358 0.904-6.154 0.080
Location
Rectum 1.00(ref.)
Left colon cancer 1.056 0.484-2.300 0.892
Right colon cancer 0.532 0.192-1.475 0.225
Stage
II 1.00(ref.)
III 0.847 0.403-1.781 0.661
a Carcinoembryonic antigen.
Table 5 The risk factors for chemotherapy-associated
lymphopenia <0.91 × 109/L in colorectal cancer by
multivariate logistic regression model
Variables Odds ratio 95% confidence intervals P-value
Pretreatment albumin
≥35 g/L 1.00(ref.)
<35 g/L 1.410 0.772-2.576 0.263
Pretreatment CEAa
<10 ng ml-1 1.00(ref.)
≥10 ng ml-1 1.885 0.984-3.610 0.056
Differentiation
Well 1.00(ref.)
Moderately 1.590 0.564-4.483 0.381
Low 2.694 0.694-10.458 0.152
Sex
Male 1.00(ref.)
Female 1.725 0.987-3.016 0.056
Age
≤49 years 1.00(ref.)
50-60 yeas 1.617 0.705-3.709 0.256
>60 years 2.872 1.344-6.136 0.006
Location
Rectum 1.00(ref.)
Left colon cancer 0.948 0.502-1.789 0.869
Right colon cancer 0.780 0.381-1.596 0.496
Stage
II 1.00(ref.)
III 0.881 0.494-1.572 0.668
a Carcinoembryonic antigen.
Chu-Yuan et al. BMC Cancer 2013, 13:177 Page 8 of 10
http://www.biomedcentral.com/1471-2407/13/177only independent risk factor for chemotherapy-associated
lymphopenia <0.91 × 109/L in colorectal cancer, suggesting
those who have a pretreatment CEA ≥10 ng ml-1 are pre-
dispose to lymphopenia <0.66 × 109/L, meanwhile those
>60 years old are predispose to lymphopenia <0.91 × 109/
L during adjuvant chemotherapy. Thus, pretreatment
CEA ≥10 ng ml-1 and age > 60 years should be taken into
account in the individualized medicine in adjuvant chemo-
therapy of CRC to reduce the risk of chemotherapy-
associated lymphopenia and improve survival. The rate of
grade 3/4 neutropenia in our study was lower than that in
the MOSAIC study (41.1%) [36]. In MOSAIC study,
FOLFOX was administered to those who have neutrophil
counts >1.5 × 109/L, while those with baseline neutrophil
counts ≥ 2.0 × 109 cells/L were included in our study. That
may contribute to the difference in the severity of
neutropenia.
However, there are some limitations in the present
study. The sample size was relatively small. Thereforethe conclusions, such as the cut-offs of lymphopenia,
should be proven by the larger, multicenter study. We
also await the further functional analyses of circulating
lymphocyte subpopulations that contribute to prognosis
of CRC receiving adjuvant chemotherapy.
Conclusions
In conclusion, our study indicated chemotherapy-associated
lymphopenia <0.66 × 109/L/0.91 × 109/L was associated
with worse prognosis in adjuvant chemotherapy of
CRC. Chemotherapy-associated lymphopenia is sup-
posed to reflect the immunosuppression state which has
an adverse impact on the anti-tumor effect and may
partly explain the failure of adjuvant chemotherapy in
CRC. Circulating lymphocyte counts should be moni-
tored during chemotherapy to guide individualized
medicine in adjuvant chemotherapy of CRC, especially
for those who have a pretreatment CEA ≥10 ng ml-1 or
those >60 years old.
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